HealthProtocols
← All protocols

GLP-1 receptor agonist therapy

Clinician-directed GLP-1 receptor agonist drugs improve glycemic control and produce large average weight losses in trials and real-world cohorts; cardiovascular outcome trials (e.g. liraglutide LEADER) anchor hard MACE and mortality signals separately from short-term wearable physiology work on resting heart rate and HRV during initiation.

Scope

GLP-1 receptor agonist (GLP-1 RA) therapy means prescription pharmacologic agonism of the GLP-1 receptor for type 2 diabetes, chronic weight management, or approved cardiovascular-risk indications (labels and molecules differ by region). Titration schedules, formulations, and dual GIP/GLP-1 products are treated as within-class variation so users find one coherent evidence hub rather than scattered near-duplicate slugs.

Obesity, HFpEF+obesity, and CKD outcome anchors (molecule/dose-specific)

  • Once-weekly semaglutide 2.4 mg (obesity without diabetes): Wilding et al. 2021 (N Engl J Med; PMID 33567185; wilding-2021-semaglutide-step1-overweight-obesity-nejm) — STEP 1 coprimary % weight loss and ≥5% responder outcomes versus placebo on a lifestyle background.
  • Dual GIP/GLP-1 tirzepatide (obesity without diabetes): Jastreboff et al. 2022 (N Engl J Med; PMID 35658024; jastreboff-2022-tirzepatide-surmount-1-obesity-nejm) — SURMOUNT-1 dose-response (5 / 10 / 15 mg weekly) versus placebo.
  • Semaglutide 2.4 mg (HFpEF with obesity): Kosiborod et al. 2023 (N Engl J Med; PMID 37622681; kosiborod-2023-semaglutide-step-hfpef-obesity-nejm) — STEP-HFpEF dual primary KCCQ-CSS and % weight change, plus 6-minute walk distance and hierarchical composite signals.
  • Semaglutide 1.0 mg (T2D + CKD): Perkovic et al. 2024 (N Engl J Med; PMID 38785209; perkovic-2024-semaglutide-flow-ckd-t2d-nejm) — FLOW primary major kidney disease events composite and confirmatory secondary hierarchy (read kidney-specific and MACE contrasts separately from STEP obesity trials).

Wearable autonomic + weight signals (12-week initiation cohort)

Grosicki et al. 2025 (Am J Physiol Heart Circ Physiol; PMID 39705534; grosicki-2025-glp1-ra-wearable-hrv-mediated-rhr) followed 66 adults starting GLP-1 RAs with WHOOP telemetry versus propensity-matched wearable controls:

  • Weight: mean ≈−10% (95% CI −11.2% to −8.5%)
  • Resting heart rate: +3.2 bpm versus controls
  • HRV: ≈−6 ms change framed by authors as statistically mediating the RHR shift
  • Activity: exploratory trends that higher weekly physical activity may attenuate GLP-1–associated RHR increases—not definitive causal proof

Liraglutide cardiovascular outcome trial (LEADER)

Marso et al. 2016 (N Engl J Med; PMID 27295427; marso-2016-leader-liraglutide-cv-outcomes-nejm) randomized 9,340 adults with type 2 diabetes at high cardiovascular risk to liraglutide or placebo on standard care (double-blind; median follow-up 3.8 years). Primary composite (CV death, nonfatal MI, nonfatal stroke) HR 0.87 (95% CI 0.78–0.97); CV death HR 0.78 (0.66–0.93); all-cause mortality HR 0.85 (0.74–0.97). Treat as liraglutide-specific efficacy context—other GLP-1 RAs require their own outcome trials.

Evidence hygiene

  • Telemetry vs hard endpoints: Grosicki et al. 2025 is 12-week wearable initiation physiology; LEADER is multi-year MACE for liraglutide in diabetes—pair them, do not substitute one for the other in clinical reasoning.
  • Prescribing: outcome trials and labels differ by molecule, indication, and region—this wiki summarizes literature anchors, not individualized medical advice.
  • Do not merge with intermittent fasting (intermittent-fasting) or time-restricted eating (time-restricted-eating)—those are behavioral eating-schedule protocols with different trial literatures.

Tertiary map

Wikipedia: Glucagon-like peptide-1 receptor agonist (wikipedia-glp-1-receptor-agonist-overview) supplies class history, molecule list, and regulatory vocabulary—numeric outcomes stay on PubMed-linked rows here.

Evidence